Raised $33M seed (Mar 2026). Owkin Dx spinout. Multimodal oncology AI analyzing pathology images + clinical data for treatment decisions. Positioned against Tempus and Foundation Medicine.
Waiv is a digital pathology AI company spun out of Owkin's diagnostic unit in March 2026 with a $33 million seed round, inheriting Owkin's proven multimodal oncology AI stack that has been validated in multiple peer-reviewed publications and clinical collaborations with major academic medical centers. The platform analyzes H&E-stained pathology slide images combined with genomic, clinical, and outcomes data to extract prognostic and predictive biomarkers that help oncologists select optimal treatments for individual cancer patients.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.